A vaccine for Lassa fever may be on the horizon, thanks to a new clinical trial jointly led by Elissa Malkin, DO, MPH, assistant research professor of medicine at the George Washington University School of Medicine and Health Sciences. With an award from trial sponsor IAVI, Malkin, along with collaborators from Brigham and Women’s Hospital in Boston, Redemption Hospital in Monrovia, Liberia, and East-West Medical Research Institute in Honolulu, Hawaii, will be testing IAVI’s experimental vaccine candidate called “rVSV∆G-LASV-GPC,” a recombinant vesicular stomatitis virus (rVSV) vector-based vaccine expressing a Lassa virus protein (LASV-GPC).
SMHS-Led Clinical Trial To Assess Immunogenicity and Safety of Lassa Fever Vaccine
August 31, 2023
George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak.
April 20, 2023
Read more information about how The George Washington Vaccine Research Unit is looking for adolescents between the ages of 12 and 17 to participate in a Mpox vaccine trial. The need for adolescents is vital for researchers to get an approved vaccine for adolescents to prevent another outbreak.
December 8, 2022
Read more about the new hope found in Phase 1 clinical trials for the HIV vaccine.